![Pamela Conley](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Pamela Conley
Gründer bei Nuvig Therapeutics, Inc.
Aktive Positionen von Pamela Conley
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Cellphire, Inc.
![]() Cellphire, Inc. BiotechnologyHealth Technology Cellphire, Inc. develops proprietary method for the long-term stabilization of platelets in the dry state. It focuses on developing stabilized cellular materials for advanced technologies in the therapeutic and diagnostic markets through its proprietary cell stabilization technology. The company was founded by Richard O. Cliff in 2005 and is headquartered in Rockville, MD. | Direktor/Vorstandsmitglied | 08.02.2022 | - |
Nuvig Therapeutics, Inc.
![]() Nuvig Therapeutics, Inc. BiotechnologyHealth Technology Nuvig Therapeutics, Inc. is a company that is focused on developing innovative therapies for patients with chronic autoimmune diseases. The company is based in Redwood City, CA. The company's goal is to induce natural mechanisms that restore immune homeostasis and rebalance immune function following inflammation. Nuvig Therapeutics was founded by Greg Coffey, Jeffrey V. Ravetch, Sheldon L. Koenig, Pamela B. Conley, Joanne M. Quan. Julie Anne Smith has been the CEO of the company since 2023. | Gründer | - | - |
Technik-/Wissenschafts-/F&E-Leiter | 04.01.2023 | - | |
Vorstandsvorsitzender | - | 04.01.2023 |
Karriereverlauf von Pamela Conley
Ehemalige bekannte Positionen von Pamela Conley
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Millennium Pharmaceuticals, Inc.
![]() Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - | - |
COR Therapeutics, Inc.
![]() COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Direktor/Vorstandsmitglied | 01.01.1991 | - |
iPierian, Inc.
![]() iPierian, Inc. Pharmaceuticals: MajorHealth Technology ierian, Inc. developed and manufactured biopharmaceutical products. The firm's lead antibody, IPN007, represents a new approach to treating neurodegenerative disease by targeting a novel form of secreted Tau protein. The company was founded in 2007 and is headquartered in South San Francisco, CA. | Technik-/Wissenschafts-/F&E-Leiter | 21.05.2012 | - |
PORTOLA PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Corporate Officer/Principal | 01.01.2003 | - |
Ausbildung von Pamela Conley
The University of Texas at Austin | Undergraduate Degree |
University of California, Berkeley | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 9 |
Operativ
Chief Tech/Sci/R&D Officer | 3 |
Corporate Officer/Principal | 2 |
Director/Board Member | 2 |
Sektoral
Health Technology | 7 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 6 |
---|---|
Portola Pharmaceuticals LLC
![]() Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Portola Pharmaceuticals, Inc. engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA. | Health Technology |
COR Therapeutics, Inc.
![]() COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Health Technology |
iPierian, Inc.
![]() iPierian, Inc. Pharmaceuticals: MajorHealth Technology ierian, Inc. developed and manufactured biopharmaceutical products. The firm's lead antibody, IPN007, represents a new approach to treating neurodegenerative disease by targeting a novel form of secreted Tau protein. The company was founded in 2007 and is headquartered in South San Francisco, CA. | Health Technology |
Millennium Pharmaceuticals, Inc.
![]() Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Cellphire, Inc.
![]() Cellphire, Inc. BiotechnologyHealth Technology Cellphire, Inc. develops proprietary method for the long-term stabilization of platelets in the dry state. It focuses on developing stabilized cellular materials for advanced technologies in the therapeutic and diagnostic markets through its proprietary cell stabilization technology. The company was founded by Richard O. Cliff in 2005 and is headquartered in Rockville, MD. | Health Technology |
Nuvig Therapeutics, Inc.
![]() Nuvig Therapeutics, Inc. BiotechnologyHealth Technology Nuvig Therapeutics, Inc. is a company that is focused on developing innovative therapies for patients with chronic autoimmune diseases. The company is based in Redwood City, CA. The company's goal is to induce natural mechanisms that restore immune homeostasis and rebalance immune function following inflammation. Nuvig Therapeutics was founded by Greg Coffey, Jeffrey V. Ravetch, Sheldon L. Koenig, Pamela B. Conley, Joanne M. Quan. Julie Anne Smith has been the CEO of the company since 2023. | Health Technology |
- Börse
- Insiders
- Pamela Conley
- Erfahrung